

---

The University of Frankfurt and the Max-Planck-Institute (MPI) in Bad Nauheim, Germany, invite for applications for **two**

## **Independent Junior Research Groups** (unabhängige Nachwuchsgruppen)

### **“Lipid Signaling”**

(key words: *cellular signaling, G protein-coupled receptors, ion channels, sphingolipids, eicosanoids, endocannabinoids, cell proliferation, apoptosis, pathogenesis of disease*)

within the newly established “Lipid Signaling Center Frankfurt” (LiFF), a joint networking project of the Goethe-University Frankfurt and the MPI for Heart and Lung Research in Bad Nauheim. The LiFF comprises multiple interdisciplinary expertises, state of the art technologies and core facilities in order to investigate the impact of lipid mediators on pathophysiology and to finally translate results from basic research towards development of innovative diagnostics and therapeutics.

Research is focused on lipids, particularly sphingolipids, endocannabinoids and arachidonic acid metabolites, on cellular signaling processes. Lipid mediators play crucial roles in highly specialized signaling cascades whose components, such as cyclo- and lipoxygenases (COX, LOX), are prominent targets for drug development. They also interfere with other signaling cascades including well known kinase signal transduction pathways. With this broad impact on diverse molecular regulatory networks, dysfunction of lipid signaling contributes to pathophysiology in various diseases. Particular foci at the LiFF are cardiovascular, oncological, and neurological disorders as well as inflammatory pain. The increasing scientific interest in lipid signaling is indicated by recent high-impact publications of LiFF members in acknowledged journals such as *N. Engl. J. Med.* (355: 1222-1232), *Nat. Med.* (12: 1269-1277), *Nature* (401: 493-497), *Nat. Med.* (14: 64-68), *J. Natl. Cancer Inst.* (98: 736-747), *Nat. Neurosci.* (10: 870-879), *Blood* (108: 1635-1642), *PNAS* (102: 13164-13169), *EMBO J* (23: 3031-3040), *J. Clin. Invest.* (115: 3634-3640).

Candidates are expected to have a Ph.D., M.D. or equivalent degree and a strong track record of internationally recognized research in the field of lipid signaling. They must hold the potential to establish an independent research program and be willing to cooperate with other groups in the center. Research is expected to focus on the impact of lipid mediators on molecular regulatory networks that relate to pathogenesis of human disease.

The research groups will be equipped with the position of the group leader, a post-doc, a Ph.D. student and an annual budget for consumables. Initial appointments are for three years with the possibility of renewal for an additional three-year period and promotion to a permanent position. Salary and social benefits will be in accordance with the University regulations for academic personnel.

The University of Frankfurt is an equal opportunity employer and wishes to increase the share of women in areas in which they are underrepresented.

Qualified candidates are invited to send their application by regular mail or e-mail to Prof. Dr. Dr. Gerd Geisslinger, Institut für Klinische Pharmakologie / LiFF, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany (Geisslinger@em.uni-frankfurt.de).